JPH0570368A - 末梢血管障害治療剤 - Google Patents
末梢血管障害治療剤Info
- Publication number
- JPH0570368A JPH0570368A JP3305565A JP30556591A JPH0570368A JP H0570368 A JPH0570368 A JP H0570368A JP 3305565 A JP3305565 A JP 3305565A JP 30556591 A JP30556591 A JP 30556591A JP H0570368 A JPH0570368 A JP H0570368A
- Authority
- JP
- Japan
- Prior art keywords
- agent
- external
- peripheral vascular
- kallidinogenase
- therapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000018262 Peripheral vascular disease Diseases 0.000 title claims abstract description 25
- 239000003814 drug Substances 0.000 title claims abstract description 20
- 229940124597 therapeutic agent Drugs 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 claims abstract description 15
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- 239000002674 ointment Substances 0.000 claims abstract description 6
- 239000006071 cream Substances 0.000 claims abstract description 5
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000001509 sodium citrate Substances 0.000 claims description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 abstract description 13
- 102000001399 Kallikrein Human genes 0.000 abstract description 6
- 108060005987 Kallikrein Proteins 0.000 abstract description 6
- 229960003709 kallidinogenase Drugs 0.000 abstract description 6
- 210000002700 urine Anatomy 0.000 abstract description 5
- 238000002347 injection Methods 0.000 abstract description 4
- 239000007924 injection Substances 0.000 abstract description 4
- 210000000496 pancreas Anatomy 0.000 abstract description 4
- 239000000243 solution Substances 0.000 abstract description 4
- 102000004190 Enzymes Human genes 0.000 abstract description 3
- 108090000790 Enzymes Proteins 0.000 abstract description 3
- 150000001860 citric acid derivatives Chemical class 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 229940088598 enzyme Drugs 0.000 abstract description 3
- 208000003782 Raynaud disease Diseases 0.000 abstract description 2
- 208000012322 Raynaud phenomenon Diseases 0.000 abstract description 2
- 208000037997 venous disease Diseases 0.000 abstract description 2
- 230000002411 adverse Effects 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 17
- 230000000694 effects Effects 0.000 description 10
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 7
- 239000000006 Nitroglycerin Substances 0.000 description 7
- 229960003711 glyceryl trinitrate Drugs 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- -1 polyethylene Polymers 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- KJCVRFUGPWSIIH-UHFFFAOYSA-N 1-naphthol Chemical group C1=CC=C2C(O)=CC=CC2=C1 KJCVRFUGPWSIIH-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- QPRGGJBGRUMFBU-UHFFFAOYSA-N 5-(diethylsulfamoyl)-2-methoxybenzenediazonium Chemical compound CCN(CC)S(=O)(=O)C1=CC=C(OC)C([N+]#N)=C1 QPRGGJBGRUMFBU-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- FYSKZKQBTVLYEQ-FSLKYBNLSA-N Kallidin Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)CCC1 FYSKZKQBTVLYEQ-FSLKYBNLSA-N 0.000 description 1
- 108010003195 Kallidin Proteins 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 102000010631 Kininogens Human genes 0.000 description 1
- 108010077861 Kininogens Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000013096 assay test Methods 0.000 description 1
- 239000000987 azo dye Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008269 hand cream Substances 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 108010051594 prolyl-phenylalanyl-arginine naphthylester Proteins 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- BTURAGWYSMTVOW-UHFFFAOYSA-M sodium dodecanoate Chemical compound [Na+].CCCCCCCCCCCC([O-])=O BTURAGWYSMTVOW-UHFFFAOYSA-M 0.000 description 1
- 229940082004 sodium laurate Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 229940100611 topical cream Drugs 0.000 description 1
- 229940042129 topical gel Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3305565A JPH0570368A (ja) | 1984-03-23 | 1991-10-25 | 末梢血管障害治療剤 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59054542A JPS60199827A (ja) | 1984-03-23 | 1984-03-23 | 人尿性カリジノゲナーゼを有効成分とする脳代謝障害改善剤 |
| JP3305565A JPH0570368A (ja) | 1984-03-23 | 1991-10-25 | 末梢血管障害治療剤 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP59054542A Division JPS60199827A (ja) | 1984-03-23 | 1984-03-23 | 人尿性カリジノゲナーゼを有効成分とする脳代謝障害改善剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH0570368A true JPH0570368A (ja) | 1993-03-23 |
| JPH0577656B2 JPH0577656B2 (enrdf_load_stackoverflow) | 1993-10-27 |
Family
ID=26395305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP3305565A Granted JPH0570368A (ja) | 1984-03-23 | 1991-10-25 | 末梢血管障害治療剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0570368A (enrdf_load_stackoverflow) |
-
1991
- 1991-10-25 JP JP3305565A patent/JPH0570368A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0577656B2 (enrdf_load_stackoverflow) | 1993-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Maack | Renal handling of low molecular weight proteins | |
| Terry et al. | Effect of tumor necrosis factor-α and interleukin-1α on heme oxygenase-1 expression in human endothelial cells | |
| Farraj et al. | Nasal administration of insulin using bioadhesive microspheres as a delivery system | |
| US6010691A (en) | Methods for enhancing permeation of a topically administered physiologically active substance | |
| RU2662564C2 (ru) | Лечение воспалительных заболеваний кожи | |
| Oyamada et al. | The role of mineralocorticoid receptor expression in brain remodeling after cerebral ischemia | |
| Jacobsen et al. | Clinical effects of octreotide compared to placebo in patients with gastrointestinal neuroendocrine tumours Report on a double‐blind, randomized trial | |
| JP4147329B2 (ja) | 液体形態の改良された安定性を有するコルチコトロピン放出因子の医薬製剤 | |
| Oberbauer et al. | Pharmacokinetics of indomethacin in the elderly | |
| EP1684681B1 (en) | A mixture for transdermal delivery of low and high molecular weight compounds | |
| EP2194970B1 (en) | Enhancement of the efficacy of therapeutic proteins | |
| US9555070B2 (en) | Pan-antiviral peptides for protein kinase inhibition | |
| EA010158B1 (ru) | Пептид, повышающий резистентность капилляров, фармацевтическая композиция на его основе и способ ее применения | |
| KR20040020077A (ko) | 특히 안과 용도로 상처와 병소의 회복 및/또는 개선요법에 적합한 아미노산 기초한 조성물 | |
| Schayer et al. | Binding and release of radioactive histamine in intact rats | |
| EP3137099B1 (en) | Dnase for use in treating vaso-occlusive crisis | |
| JPH0570368A (ja) | 末梢血管障害治療剤 | |
| JP2002526423A (ja) | オキシブチニン配合物及びその使用方法 | |
| JP2010526857A (ja) | ジヨードチロニンを含んでなる新規な医薬組成物及びその治療的使用 | |
| US7807635B1 (en) | Pan-antiviral peptides for protein kinase inhibition | |
| JPS60199827A (ja) | 人尿性カリジノゲナーゼを有効成分とする脳代謝障害改善剤 | |
| Gomez et al. | Reduced cholecystokinin mediates the inhibition of pancreatic growth induced by bile salts | |
| EP0270639A1 (en) | Pharmaceutical composition for the nasal administration of heparin and method for treatment of patients | |
| KR20210067153A (ko) | 알파-솔라닌을 포함하는 남성 생식기 질환의 예방 또는 치료용 약학적 조성물 | |
| Hidvégi et al. | Inhibition of the complement activation by an adrenal androgen, dehydroepiandrosterone |